Pharma
1 min read

FDA approves Lupin’s Sevelamer Hydrochloride Tablets, 800 mg

Sevelamer Hydrochloride Tablets, 800 mg is a generic equivalent of Renagel Tablets, 800 mg of Genzyme Corporation

ETHealthWorld

Published On Mar 2, 2022 at 06:30 PM IST

Mumbai: Lupin Limited announced the launch of Sevelamer Hydrochloride Tablets, 800 mg, having received an approval from the United States Food and Drug Administration (FDA). The product will be manufactured at Lupin’s facility in Nagpur, India.
Sevelamer Hydrochloride Tablets, 800 mg is a generic equivalent of Renagel® Tablets, 800 mg of Genzyme Corporation. Sevelamer Hydrochloride Tablets, 800 mg (RLD: Renagel) had estimated annual sales of $75 million in the US (IQVIA MAT December 2021).